Biomarkers

Area of Science:

• Neuroscience
• Biomarker Discovery
• Diagnostic Accuracy

Background:

• Distinguishing Alzheimer's disease (AD) from other neurodegenerative dementias is clinically challenging.
• Plasma biomarkers offer a less invasive alternative to traditional diagnostic methods like CSF analysis and PET imaging.
• Evaluating the diagnostic efficacy of various plasma biomarkers is crucial for early and accurate AD diagnosis.

Purpose of the Study:

• To assess the diagnostic performance of plasma biomarkers in differentiating AD from other neurodegenerative conditions.
• To compare the efficacy of SIMOA and Lumipulse detection methods for blood biomarker measurement.
• To determine if plasma biomarkers can predict AD pathology with accuracy comparable to established methods.

Main Methods:

• Recruitment of 292 patients from a hospital dementia cohort with diverse diagnoses including AD, CAA, CJD, FTD, HDLS, NIID, NPH, VAD, and undetermined etiology.
• Measurement of plasma biomarkers (Aβ42/40, pTau181, pTau217, GFAP, NFL) using SIMOA and Lumipulse kits.
• Statistical comparison of biomarker levels across diagnostic groups and correlation with CSF and PET imaging results.

Main Results:

• Plasma pTau217 demonstrated the most significant difference between AD and other neurodegenerative diseases.
• Elevated plasma pTau217 levels were observed in specific conditions like CAA and CJD, comparable to AD.
• Plasma pTau217 accurately predicted CSF Aβ status (accuracy >0.9) and Aβ PET/tau PET classifications (accuracy up to 0.977).
• Strong correlations were found between SIMOA and Lumipulse measurements for all biomarkers, especially pTau217.

Conclusions:

• Plasma pTau217 is a highly effective biomarker for differentiating AD pathology in dementia patients.
• The diagnostic accuracy of plasma pTau217 is comparable to cerebrospinal fluid (CSF) biomarkers and positron emission tomography (PET) imaging.
• Blood-based pTau217 offers a promising, minimally invasive tool for AD diagnosis and management.